Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development
Antibody Therapeutics · 28.03.2025 · 8 (2) · 99-110
DOI: 10.1093/abt/tbaf005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 09.03.2025. Verfasst von Lili Wen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioconjugate Product Development and Manufacturing, WuXi XDC Co., Ltd., Wuxi, Jiangsu, P.R. China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: WuXi XDC.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) have emerged as a rapidly expanding class of therapeutics driven by their superior specificity and clinical efficacy. 14 out of 16 commercially approved ADCs are formulated as lyophilized forms because ADC is generally considered to be less stable than unmodified antibody. The formulation development for ADCs, particularly liquid formulation, presents unique challenges due to their intricate structural complexity, physicochemical properties, and degradation pathways. This review provides the first comprehensive analysis of formulation strategies employed in commercial ADCs. Furthermore, this review discusses the key areas of focus for ADCs throughout the formulation development workflow, spanning from the initial formulation development to the final stage of drug product manufacturing. In addition, we identify and analyze the distinctive technical challenges in ADC formulation development compared to unconjugated antibody, while proposing potential solutions to these challenges. Finally, we offer strategic perspectives on future directions in ADC formulation development to advance this promising therapeutic modality.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Bioconjugate Product Development and Manufacturing, WuXi XDC Co., Ltd., Wuxi, Jiangsu, P.R. China.
- Business Enablement North America, XDC ConjuTech USA LLC, Middletown, DE, United States.
ORCID-Profile: Chunyuan Jia
Förderung
- WuXi XDC
Zitieren
APA
Wen, L., Zhang, Y., Sun, C., Wang, S. S., Gong, Y., Jia, C., & Luo, J. (2025). Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development. Antibody Therapeutics, 8(2), 99-110. https://doi.org/10.1093/abt/tbaf005
Vancouver
Wen L, Zhang Y, Sun C, Wang SS, Gong Y, Jia C, et al. Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development. Antibody Therapeutics. 2025;8(2):99-110. doi:10.1093/abt/tbaf005
BibTeX
@article{Wen2025,
author = {Wen, Lili and Zhang, Yuanyuan and Sun, Chenxi and Wang, Shawn Shouye and Gong, Yuhui and Jia, Chunyuan and Luo, Jianjun},
title = {Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development},
journal = {Antibody Therapeutics},
year = {2025},
volume = {8},
number = {2},
pages = {99--110},
doi = {10.1093/abt/tbaf005}
}
EUVIMED